最新观点
Insights From Our Experts
Articles
What’s next for ICER? Pharmaceutical pricing watchdog to venture beyond the pill.
Earlier in the month, the Institute for Clinical and Economic Review (ICER) issued a call for public input to help identify and prioritize non-drug topics for ICER assessments in 2020. It may seem like the ICER…
Ask the Expert – Specialty Pharmacies and Specialty Distributors
According to a recent study from Health Strategies Insights by EVERSANA, 35%-45% of pipeline drugs are infusions and injectables that require nursing services, patient education, cold chain, new reimbursement measures and sites of care. Where is…
Developing an Optimal Hub to Ensure Product Access
Prior to launching a new Hub, our client, a global biopharmaceutical company, needed to ensure that the services offered would be superior to those of other companies and ensure their product’s access in an increasingly competitive…
The Four Biggest Recruitment Issues for Clinical Operations Teams … And How to Solve Them.
Eighty percent of clinical trials in the United States fail to meet their patient recruitment timelines [1, 2] and 15-20% of activated clinical trial sites never enroll a single patient. [2] Meanwhile, 50% of clinical trial…
WHAT IF… We Broke the Silos Throughout Pre- to Post-Commercialization?
In their special November/December issue, PharmaVOICE asked industry leaders to think beyond the status quo and provide insight into what needs to happen to achieve aspirational goals and evolve the healthcare industry in 2020. In the…
Bringing Humanity Back to Healthcare
Posted on 11 月 22, 201911/22/19
As the healthcare industry shifts to patient-centered care, PharmaVOICE asks the question: how do we bring humanity or the human element back into healthcare? As patients become more engaged healthcare consumers and patient advocacy groups more…
After FDA Approval, Can Gene Therapies Achieve Marketing Success?
Without a doubt, gene therapy is transforming healthcare by revolutionizing patient care from conventional treatment models to curative therapy models. There are more than 7,000 distinct types of rare and genetic diseases and 400+ million individuals…
Decoding ICER: Successful Pharma Engagement with ICER for U.S. HTA Review
How pharmaceutical and Biotech companies engaged ICER drives the outcome. Reactive responses to ICER review have led to poor outcomes and numerous downstream impacts to payer access and pricing. Cohesive enterprise engagement has demonstrated significantly better…
Integrated Delivery Networks: Learning to Engage With a New Customer With Very Different Needs
As the healthcare provider landscape rapidly evolves to deliver on the promises of value-based care and efficiencies of scale, integrated delivery networks (IDNs) have emerged as a dominant force in the US market. Meanwhile, biopharmaceutical manufacturers…
Challenges and Best Practices in Managing Value Based Contracts
Manufacturers face a variety of hurdles when negotiating value based contracts: from data access and standardization, deal structure variation, payment variability and scheduling, to changing laws and regulations. And, as the industry shifts to value-driven healthcare,…